Eribulin antibody-drug conjugates and methods of use
US11572414B2 · kind B2 · utility
0Cited by
12References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 6, 2020 |
| Grant date | Feb 7, 2023 |
| Priority date | — |
| Expiry date | Apr 9, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates such as those comprising eribulin) thereof that bind to mesothelin are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the compositions provided herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.